Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate.

Amsterdam JD, Shults J, Brunswick DJ, Hundert M.

Bipolar Disord. 2004 Feb;6(1):75-81.

PMID:
14996144
2.
4.

Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.

Amsterdam JD, Garcia-España F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Schweizer E, Beasley C.

J Clin Psychopharmacol. 1998 Dec;18(6):435-40.

PMID:
9864074
5.

Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study.

Amsterdam JD, Shults J.

J Clin Psychopharmacol. 2008 Apr;28(2):171-81. doi: 10.1097/JCP.0b013e318166c4e6.

PMID:
18344727
6.

Antidepressant monotherapy for bipolar type II major depression.

Amsterdam JD, Brunswick DJ.

Bipolar Disord. 2003 Dec;5(6):388-95. Review.

PMID:
14636362
7.

Venlafaxine monotherapy in women with bipolar II and unipolar major depression.

Amsterdam JD, Garcia-España F.

J Affect Disord. 2000 Sep;59(3):225-9.

PMID:
10854639
8.

Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression.

Szuba MP, Amsterdam JD, Fernando AT 3rd, Gary KA, Whybrow PC, Winokur A.

J Clin Psychopharmacol. 2005 Aug;25(4):325-30. Erratum in: J Clin Psychopharmacol. 2005 Dec;25(6):538. Fernando, Antonio T 3rd [added]; Gary, Keith A [added]; Whybrow, Peter C [added]; Winokur, Andrew [added].

PMID:
16012274
9.

Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial.

Amsterdam JD, Wang CH, Shwarz M, Shults J.

J Affect Disord. 2009 Jan;112(1-3):219-30. doi: 10.1016/j.jad.2008.03.029. Epub 2008 May 16.

PMID:
18486235
10.
11.

Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode.

Amsterdam J.

J Clin Psychopharmacol. 1998 Oct;18(5):414-7.

PMID:
9790160
12.

Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression.

Dunner DL, D'Souza DN, Kajdasz DK, Detke MJ, Russell JM.

J Affect Disord. 2005 Jul;87(1):115-9. Review.

PMID:
15967235
13.

Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.

Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C.

J Clin Psychiatry. 2006 Nov;67(11):1767-75.

PMID:
17196058
14.

Role of risperidone in bipolar II: an open 6-month study.

Vieta E, Gastó C, Colom F, Reinares M, Martínez-Arán A, Benabarre A, Akiskal HS.

J Affect Disord. 2001 Dec;67(1-3):213-9.

PMID:
11869771
15.

Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder.

Nemets B, Bersudsky Y, Belmaker RH.

J Clin Psychiatry. 2005 May;66(5):586-90.

PMID:
15889944
16.

Antidepressant-induced mania in bipolar patients: identification of risk factors.

Henry C, Sorbara F, Lacoste J, Gindre C, Leboyer M.

J Clin Psychiatry. 2001 Apr;62(4):249-55.

PMID:
11379838
17.
18.

A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.

Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R.

Health Technol Assess. 2008 May;12(14):iii-iv, ix-60.

19.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
20.

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.

Mao PX, Tang YL, Jiang F, Shu L, Gu X, Li M, Qian M, Ma C, Mitchell PB, Cai ZJ.

Depress Anxiety. 2008;25(1):46-54.

PMID:
17149753

Supplemental Content

Support Center